Effects of ABCB1 and ABCG2 polymorphisms on the pharmacokinetics of abemaciclib-Reference-Cited by-同舟云学术

Effects of ABCB1 and ABCG2 polymorphisms on the pharmacokinetics of abemaciclib

Published:2022-05-09 Issue:8 Volume:78 Page:1239-1247
ISSN:0031-6970
Container-title:European Journal of Clinical Pharmacology
language:en
Short-container-title:Eur J Clin Pharmacol

Author:

Maeda Akimitsu^ORCID,Ando Hitoshi^ORCID,Irie Kei^ORCID,Hashimoto Naoya,Morishige Jun-ichi,Fukushima Shoji,Okada Akira,Ebi Hiromichi^ORCID,Matsuzaki Masahide,Iwata Hiroji,Sawaki Masataka

Funder

Aichi Cancer Research Foundation

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s00228-022-03331-0.pdf

Reference33 articles.

1. Johnston S, Martin M, Di Leo A, Im SA, Awada A, Forrester T, Frenzel M, Hardebeck MC, Cox J, Barriga S, Toi M, Iwata H, Goetz MP (2019) MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer. NPJ Breast Cancer 5:5. https://doi.org/10.1038/s41523-018-0097-z

2. Sledge GW Jr, Toi M, Neven P, Sohn J, Inoue K, Pivot X, Burdaeva O, Okera M, Masuda N, Kaufman PA, Koh H, Grischke EM, Frenzel M, Lin Y, Barriga S, Smith IC, Bourayou N, Llombart-Cussac A (2017) MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+/HER2-advanced breast cancer who had progressed while receiving endocrine therapy. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 35(25):2875–2884. https://doi.org/10.1200/jco.2017.73.7585

3. Goetz MP, Toi M, Campone M, Sohn J, Paluch-Shimon S, Huober J, Park IH, Tredan O, Chen SC, Manso L, Freedman OC, Garnica Jaliffe G, Forrester T, Frenzel M, Barriga S, Smith IC, Bourayou N, Di Leo A (2017) MONARCH 3: abemaciclib as initial therapy for advanced breast cancer. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 35(32):3638–3646. https://doi.org/10.1200/jco.2017.75.6155

4. Sledge GW Jr, Toi M, Neven P, Sohn J, Inoue K, Pivot X, Burdaeva O, Okera M, Masuda N, Kaufman PA, Koh H, Grischke EM, Conte P, Lu Y, Barriga S, Hurt K, Frenzel M, Johnston S, Llombart-Cussac A (2020) The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor-positive, ERBB2-negative breast cancer that progressed on endocrine therapy-MONARCH 2: a randomized clinical trial. JAMA Oncol 6(1):116–124. https://doi.org/10.1001/jamaoncol.2019.4782

5. Fujiwara Y, Tamura K, Kondo S, Tanabe Y, Iwasa S, Shimomura A, Kitano S, Ogasawara K, Turner PK, Mori J, Asou H, Chan EM, Yamamoto N (2016) Phase 1 study of abemaciclib, an inhibitor of CDK 4 and 6, as a single agent for Japanese patients with advanced cancer. Cancer Chemother Pharmacol 78(2):281–288. https://doi.org/10.1007/s00280-016-3085-8

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Abemaciclib pharmacology and interactions in the treatment of HR+/HER2− breast cancer: a critical review;Therapeutic Advances in Drug Safety;2024-01

2. Association of ADME gene polymorphisms on toxicity to CDK4/6 inhibitors in patients with HR+ HER2- metastatic breast cancer;Biomedicine & Pharmacotherapy;2023-11

3. Advances in the structure, mechanism and targeting of chemoresistance-linked ABC transporters;Nature Reviews Cancer;2023-09-15

4. Differences in metabolic transport and resistance mechanisms of Abemaciclib, Palbociclib, and Ribociclib;Frontiers in Pharmacology;2023-07-05

5. An Improved Technique for Genotyping the ABCB1 Gene Variant of Exon 21;Methods and Protocols;2023-05-26